Insights

Strategic partnerships Leverage ImmunoGenesis recent collaboration with BostonGene and leadership additions to position co-development and data-driven trial support services, targeting accelerated clinical development for IMGS-001 and related immunotherapies.

Board strength New appointments to the board including Reza Mazhari and Mike Davis signal enhanced governance and strategic oversight, creating openings for advisory and investor relations services, as well as potential funding strategy collaborations.

Clinical leadership Appointment of a Chief Medical Officer with oncology-focused expertise provides a doorway to clinical operations partnerships, medical affairs outsourcing, and early access program planning for cold tumor indications.

Pipeline focus Lead program IMGS-001 targeting immune-excluded tumors aligns with unmet market needs; explore opportunities in companion diagnostics, biomarker strategy, and payer-oriented value dossiers to support faster reimbursement.

Growth signals Recent press releases and AACR attendance indicate active market signaling and visibility; offer trade show partnerships, sponsor opportunities, and research collaboration proposals to expand clinical and commercial reach.

ImmunoGenesis, Inc. Tech Stack

ImmunoGenesis, Inc. uses 8 technology products and services including Google Ads, Sucuri, RSS, and more. Explore ImmunoGenesis, Inc.'s tech stack below.

Google Ads

Advertising

Sucuri

Content Delivery Network

RSS

Content Management System

WordPress

Content Management System

Microsoft 365

Element UI

Javascript Frameworks

jQuery

Javascript Libraries

Google Tag Manager

Tag Management

ImmunoGenesis, Inc. Email Formats	Example	Percentage
First.Last@immunogenesis.com	John.Doe@immunogenesis.com	100%

ImmunoGenesis, Inc. Email Formats

Example

Percentage

First.Last@immunogenesis.com

John.Doe@immunogenesis.com

100%

Frequently Asked Questions

What is ImmunoGenesis, Inc.'s official website and social media links?

ImmunoGenesis, Inc.'s official website is immunogenesis.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does ImmunoGenesis, Inc. generate?

As of October 2026, ImmunoGenesis, Inc.'s annual revenue is estimated to be $10M - $25M.

What is ImmunoGenesis, Inc.'s SIC code and NAICS code?

ImmunoGenesis, Inc.'s SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does ImmunoGenesis, Inc. have currently?

As of October 2026, ImmunoGenesis, Inc. has approximately 15 employees across 1 continents, including North America. Key team members include Ceo, President And Bod Member: J. B., Chief Scientific Officer: F. P. and Senior Vice President, Clinical Development: C. S. Explore ImmunoGenesis, Inc.'s employee directory with LeadIQ.

What industry does ImmunoGenesis, Inc. belong to?

ImmunoGenesis, Inc. operates in the Biotechnology Research industry.

What technology does ImmunoGenesis, Inc. use?

ImmunoGenesis, Inc.'s tech stack includes Google Ads, Sucuri, RSS, WordPress, Microsoft 365, Element UI, jQuery and Google Tag Manager.

What is ImmunoGenesis, Inc.'s email format?

ImmunoGenesis, Inc.'s email format typically follows the pattern of First.Last@immunogenesis.com. Find more ImmunoGenesis, Inc. email formats with LeadIQ.

How much funding has ImmunoGenesis, Inc. raised to date?

As of October 2026, ImmunoGenesis, Inc. has raised $45M in funding. The last funding round occurred on Dec 04, 2025 for $5.7M.

When was ImmunoGenesis, Inc. founded?

ImmunoGenesis, Inc. was founded in 2019.

ImmunoGenesis, Inc.

Q: What is ImmunoGenesis, Inc.'s official website and social media links?

ImmunoGenesis, Inc.'s official website is immunogenesis.com. ImmunoGenesis, Inc. has social profiles on LinkedIn.

Q: How many employees does ImmunoGenesis, Inc. have currently?

ImmunoGenesis, Inc. has approximately 15 employees.

Q: What technology does ImmunoGenesis, Inc. use?

ImmunoGenesis, Inc.'s tech stack includes Floating UI, Priority Hints, Font Awesome, Apache, PHP.

Q: What is ImmunoGenesis, Inc.'s NAICS code?

ImmunoGenesis, Inc.'s NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).

Biotechnology ResearchTexas, United States11-50 Employees

ImmunoGenesis, Inc. is a clinical-stage biotechnology company based in Houston, Texas, focused on immuno-oncology with an emphasis on immune-excluded or cold tumors. It develops therapeutic approaches designed to overcome mechanisms that suppress the immune response in these tumors, aiming to trigger a robust anti-tumor immune reaction. The company pursues a drug development strategy rooted in the specific pathology of cold tumors, seeking to reimagine how such cancers are treated.

Its target patients are those whose cancers exhibit immune exclusion and resistance to current immunotherapies; the work centers on the company’s lead program IMGS-001. ImmunoGenesis operates within the biotechnology research industry and engages in partnerships to accelerate development, including a strategic collaboration with BostonGene announced in April 2026 to advance IMGS-001. The organization maintains a relatively small to mid-sized team and is active in clinical development efforts from its Houston base.

Insights

Similar companies to ImmunoGenesis, Inc.